References
1. Chawanpaiboon S, Vogel JP, Moller
AB, Lumbiganon P, Petzold M, Hogan D, et al. Global, regional, and
national estimates of levels of preterm birth in 2014: a systematic
review and modelling analysis. Lancet Glob Health. 2019
Jan;7(1):e37-e46.
2. Platt MJ. Outcomes in preterm
infants. Public Health. 2014 May;128(5):399-403.
3. UN Inter-agency Group for Child
Mortality Estimation. Levels and trends in child mortality: report 2017,
estimates developed by the UN Inter-agency Group for child mortality
estimation. . New York: United Nations Children’s Fund; 2017.
4. Glass HC, Costarino AT, Stayer SA,
Brett CM, Cladis F, Davis PJ. Outcomes for extremely premature infants.
Anesth Analg. 2015 Jun;120(6):1337-51.
5. Crowley P. Prophylactic
corticosteroids for preterm birth. Cochrane Database Syst Rev.
2000(2):CD000065.
6. Collaborators WAT. The World Health
Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes
in preterm Newborns) Trial: a multi-country, multi-centre, two-arm,
parallel, double-blind, placebo-controlled, individually randomized
trial of antenatal corticosteroids for women at risk of imminent birth
in the early preterm period in hospitals in low-resource countries.
Trials. 2019 Aug 16;20(1):507.
7. WHO. Recommendations on
Interventions to Improve Preterm Birth Outcomes. Evidence and
recommendations 2015 [cited 2018 12/2018]; Available from:https://www.who.int/reproductivehealth/publications/maternal_perinatal_health/preterm-birth-guideline/en/
8. Managing complications in pregnancy
and childbirth: a guide for midwives and doctors. 2nd ed. Geneva: World
Health Organization; 2017.
9. Brownfoot FC, Gagliardi DI, Bain E,
Middleton P, Crowther CA. Different corticosteroids and regimens for
accelerating fetal lung maturation for women at risk of preterm birth.
Cochrane Database Syst Rev. 2013 Aug 29(8):CD006764.
10. Roberts D, Brown J, Medley N,
Dalziel SR. Antenatal corticosteroids for accelerating fetal lung
maturation for women at risk of preterm birth. Cochrane Database Syst
Rev. 2017 Mar 21;3:CD004454.
11. Roberts D, Dalziel S. Antenatal
corticosteroids for accelerating fetal lung maturation for women at risk
of preterm birth. Cochrane Database Syst Rev. 2006 Jul 19(3):CD004454.
12. Crowther CA, Ashwood P, Andersen
CC, Middleton PF, Tran T, Doyle LW, et al. Maternal intramuscular
dexamethasone versus betamethasone before preterm birth (ASTEROID): a
multicentre, double-blind, randomised controlled trial. Lancet Child
Adolesc Health. 2019 Sep 12.
13. Mirzamoradi M, Hasani Nejhad F,
Jamali R, Heidar Z, Bakhtiyari M. Evaluation of the effect of antenatal
betamethasone on neonatal respiratory morbidities in late preterm
deliveries (34-37 weeks). The journal of maternal-fetal & neonatal
medicine : the official journal of the European Association of Perinatal
Medicine, the Federation of Asia and Oceania Perinatal Societies, the
International Society of Perinatal Obstetricians. 2019:1-8.
14. Ontela V, Dorairajan G, Bhat VB,
Chinnakali P. Effect of Antenatal Steroids on Respiratory Morbidity of
Late Preterm Newborns: A Randomized Controlled Trial. Journal of
Tropical Pediatrics. 2018;64(6):531-8.
15. Hutton B, Salanti G, Caldwell DM,
Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement
for reporting of systematic reviews incorporating network meta-analyses
of health care interventions: checklist and explanations. Ann Intern
Med. 2015 Jun 2;162(11):777-84.
16. Binder LM, Iverson GL, Brooks BL.
To Err is Human: “Abnormal” Neuropsychological Scores and Variability
are Common in Healthy Adults. Archives of Clinical Neuropsychology.
2009;24(1):31-46.
17. Ciapponi A, Glujovsky D, Bardach
A, García Martí S, Comande D. EROS: a new software for early stage of
systematic reviews. HTAi 2011 Conference; 2011 June 27-29, 2011; Rio de
Janeiro: Health Technology Assessment International (HTAi); 2011.
18. Covidence systematic review
software. Melbourne, Australia: Veritas Health Innovation.
19. Chaimani A, Caldwell DM, Li T,
Higgins JP, Salanti G. Chapter 11: Undertaking network meta-analyses.
In: Higgins J, Thomas J, Chandler J, MS. C, Li T, Page M, et al.,
editors. Cochrane Handbook for Systematic Reviews of Interventions
Version 6 [updated September 2018]
Cochrane; 2018.
20. Higgins JP, Thompson SG.
Quantifying heterogeneity in a meta-analysis. Stat Med. 2002 Jun
15;21(11):1539-58.
21. Baker SG, Kramer BS. The
transitive fallacy for randomized trials: if A bests B and B bests C in
separate trials, is A better than C? BMC Med Res Methodol. 2002 Nov
13;2:13.
22. Higgins JP, Jackson D, Barrett
JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network
meta-analysis: concepts and models for multi-arm studies. Res Synth
Methods. 2012 Jun;3(2):98-110.
23. Veroniki AA, Vasiliadis HS,
Higgins JP, Salanti G. Evaluation of inconsistency in networks of
interventions. Int J Epidemiol. 2013 Feb;42(1):332-45.
24. Dias S, Welton NJ, Caldwell DM,
Ades AE. Checking consistency in mixed treatment comparison
meta-analysis. Stat Med. 2010 Mar 30;29(7-8):932-44.
25. Turner RM, Davey J, Clarke MJ,
Thompson SG, Higgins JP. Predicting the extent of heterogeneity in
meta-analysis, using empirical data from the Cochrane Database of
Systematic Reviews. Int J Epidemiol. 2012 Jun;41(3):818-27.
26. World Bank Country and Lending
Groups. 2019 [cited 10.20/2019; Available from:https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups
27. Chaimani A, Higgins JP, Mavridis
D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in
STATA. PLoS One. 2013;8(10):e76654.
28. Trinquart L, Attiche N, Bafeta A,
Porcher R, Ravaud P. Uncertainty in Treatment Rankings: Reanalysis of
Network Meta-analyses of Randomized Trials. Ann Intern Med. 2016 May
17;164(10):666-73.
29. Veroniki AA, Straus SE, Rucker G,
Tricco AC. Is providing uncertainty intervals in treatment ranking
helpful in a network meta-analysis? J Clin Epidemiol. 2018
Aug;100:122-9.
30. Veroniki AA, Straus SE, Fyraridis
A, Tricco AC. The rank-heat plot is a novel way to present the results
from a network meta-analysis including multiple outcomes. J Clin
Epidemiol. 2016 Aug;76:193-9.
31. Lunn DJ, Thomas A, Best N,
Spiegelhalter D. WinBUGS - A Bayesian modelling framework: Concepts,
structure, and extensibility. Statistics and Computing. 2000
2000/10/01;10(4):325-37.
32. Review Manager (RevMan).
[Computer program] Version 53 Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration; 2014.
33. Puhan MA, Schunemann HJ, Murad
MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working
Group approach for rating the quality of treatment effect estimates from
network meta-analysis. BMJ. 2014;349:g5630.
34. Brignardello-Petersen R, Bonner
A, Alexander PE, Siemieniuk RA, Furukawa TA, Rochwerg B, et al. Advances
in the GRADE approach to rate the certainty in estimates from a network
meta-analysis. J Clin Epidemiol. 2018 Jan;93:36-44.
35. Effect of antenatal dexamethasone
administration on the prevention of respiratory distress syndrome. Am J
Obstet Gynecol. 1981 Oct 1;141(3):276-87.
36. Amorim MMR, Santosa LC, Faúndes
A. Corticosteroid therapy for prevention of respiratory distress
syndrome in severe preeclampsia. American Journal of Obstetrics and
Gynecology. 1999 1999/05;180(5):1283-8.
37. Attawattanakul N, Tansupswatdikul
P. Effects of antenatal dexamethasone on respiratory distress in late
preterm infant: a randomized controlled trial. hai Journal of Obstetrics
and Gynaecology. 2015;23(1):25‐33.
38. Balci O, Ozdemir S, Mahmoud AS,
Acar A, Colakoglu MC. The Effect of Antenatal Steroids on Fetal Lung
Maturation between the 34th and 36th Week of Pregnancy. Gynecologic and
Obstetric Investigation. 2010;70(2):95-9.
39. Block MF, Kling OR, Crosby WM.
Antenatal glucocorticoid therapy for the prevention of respiratory
distress syndrome in the premature infant. Obstet Gynecol. 1977
Aug;50(2):186-90.
40. Cararach V, Botet F, Sentis J,
Carmona F. A multicenter, prospective and randomized study in premature
rupture of membranes (PROM). Maternal and perinatal complications.
International journal of gynaecology and obstetrics. 1991;36 Suppl:267.
41. Carlan SJ, Parsons M, O’Brien WF,
Krammer J. Pharmacologic pulmonary maturation in preterm premature
rupture of membranes. American journal of obstetrics and gynecology.
1991;164:371.
42. Chen C-Y, Wang K-G, Chang T-Y,
Chen C-P, Loo J-H. Effects of Antenatal Betamethasone and Dexamethasone
in Preterm Neonates. Taiwanese Journal of Obstetrics and Gynecology.
2005 2005/09/01/;44(3):247-51.
43. Danesh A, Janghorbani M,
Khalatbari S. Effects of antenatal corticosteroids on maternal serum
indicators of infection in women at risk for preterm delivery: A
randomized trial comparing betamethasone and dexamethasone. J Res Med
Sci. 2012 Oct;17(10):911-7.
44. Doran TA, Swyer P, MacMurray B,
Mahon W, Enhorning G, Bernstein A, et al. Results of a double-blind
controlled study on the use of betamethasone in the prevention of
respiratory distress syndrome. American Journal of Obstetrics and
Gynecology. 1980 1980/02;136(3):313-20.
45. Egerman RS, Walker RA, Mercer BM,
Doss JL, Sibai BM, Andersen RA. Comparison between oral and
intramuscular dexamethasone in suppressing unconjugated estriol levels
during the third trimester. Am J Obstet Gynecol. 1998 Nov;179(5):1234-6.
46. Elimian A, Garry D, Figueroa R,
Spitzer A, Wiencek V, Quirk JG. Antenatal betamethasone compared with
dexamethasone (betacode trial): a randomized controlled trial. Obstet
Gynecol. 2007 Jul;110(1):26-30.
47. Fekih M, Chaieb A, Sboui H,
Denguezli W, Hidar S, Khairi H. [Value of prenatal corticotherapy in
the prevention of hyaline membrane disease in premature infants.
Randomized prospective study]. Tunis Med. 2002 May;80(5):260-5.
48. Gamsu HR, Mullinger BM, Donnai P,
Dash CH. Antenatal administration of betamethasone to prevent
respiratory distress syndrome in preterm infants: report of a UK
multicentre trial. British journal of obstetrics and gynaecology.
1989;96(4):401‐10.
49. Garite TJ, Rumney PJ, Briggs GG,
Harding JA, Nageotte MP, Towers CV, et al. A randomized,
placebo-controlled trial of betamethasone for the prevention of
respiratory distress syndrome at 24 to 28 week’s gestation. American
Journal of Obstetrics and Gynecology. 1992 1992/02;166(2):646-51.
50. Goodner DM. Antenatal steroids in
the treatment of respiratory distress syndrome. 9th world congress of
gynecology and obstetrics; 1979 october 26-31; tokyo, japan. 1979:362.
51. Gyamfi-Bannerman C, Thom EA,
Blackwell SC, Tita AT, Reddy UM, Saade GR, et al. Antenatal
Betamethasone for Women at Risk for Late Preterm Delivery. New England
journal of medicine. 2016;374(14):1311‐20.
52. Kari MA, Hallman M, Eronen M,
Teramo K, Virtanen M, Koivisto M, et al. Prenatal dexamethasone
treatment in conjunction with rescue therapy of human surfactant: a
randomized placebo-controlled multicenter study. Pediatrics.
1994;93(5):730‐6.
53. Khandelwal M, Chang E, Hansen C,
Hunter K, Milcarek B. Betamethasone dosing interval: 12 or 24 hours
apart? A randomized, noninferiority open trial. American Journal of
Obstetrics & Gynecology. 2012;206(3):201.e1-.e11.
54. Khazardoust S, Javadian P,
Salmanian B, Zandevakil F, Abbasalizadeh F, Alimohamadi S, et al. A
clinical randomized trial on endocervical inflammatory cytokines and
betamethasone in prime-gravid pregnant women at risk of preterm labor.
Iranian journal of immunology. 2012;9(3):199‐207.
55. Lewis D, Brody K, Edwards M,
Brouillette R, Burlison S, London S. Preterm premature ruptured
membranes: A randomized trial of steroids after treatment with
antibiotics. Obstetrics & Gynecology. 1996 1996/11;88(5):801-5.
56. Liggins GC, Howie RN. A
controlled trial of antepartum glucocorticoid treatment for prevention
of the respiratory distress syndrome in premature infants. Pediatrics.
1972;50:515‐25.
57. Lopez L, Rojas L, Rodriguez V,
Sanchez J. Use of corticoids in preterm pregnancy with premature rupture
of membranes. Revista colombiana de obstetricia y ginecologia.
1989;40:147‐51.
58. Magee LA, Dawes GS, Moulden M,
Redman CW. A randomised controlled comparison of betamethasone with
dexamethasone: effects on the antenatal fetal heart rate. Br J Obstet
Gynaecol. 1997 Nov;104(11):1233-8.
59. Mansouri M, Seyedolshohadaei F,
Company F, Setare S, Mazhari S. Effect of antenatal Betamethasone on
prevention of respiratory distress syndrome among neonates with
gestational age of 35-36 weeks. Journal of Gorgan University of Medical
Sciences. 2010;12(3):Pe18-Pe23, En109.
60. Morales WJ, Angel JL, O’Brien WF,
Knuppel RA. Use of ampicillin and corticosteroids in premature rupture
of membranes: a randomized study. Obstetrics and gynecology. 1989;73(5
Pt 1):721‐6.
61. Mulder EJ, Derks JB, Visser GH.
Antenatal corticosteroid therapy and fetal behaviour: a randomised study
of the effects of betamethasone and dexamethasone. Br J Obstet Gynaecol.
1997 Nov;104(11):1239-47.
62. Mushkat Y, Ascher-Landsberg J,
Keidar R, Carmon E, Pauzner D, David MP. The effect of betamethasone
versus dexamethasone on fetal biophysical parameters. Eur J Obstet
Gynecol Reprod Biol. 2001 Jul;97(1):50-2.
63. Nelson LH, Meis PJ, Hatjis CG,
Ernest JM, Dillard R, Schey HM. Premature rupture of membranes: a
prospective, randomized evaluation of steroids, latent phase, and
expectant management. Obstetrics and gynecology. 1985;66(1):55‐8.
64. Parsons MT, Sobel D, Cummiskey K,
Constantine L, Roitman J. Steroid, antibiotic and tocolytic vs no
steroid, antibiotic and tocolytic management in patients with preterm
PROM at 25-32 weeks. Proceedings of 8th annual meeting of the society of
perinatal obstetricians; 1988 feb 3-6; las vegas, nevada, USA. 1988:44.
65. Pattinson RC, Makin JD, Funk M,
Delport SD, Macdonald AP, Norman K, et al. The use of dexamethasone in
women with preterm premature rupture of membranes–a multicentre,
double-blind, placebo-controlled, randomised trial. Dexiprom Study
Group. South African medical journal. 1999;89(8):865‐70.
66. Porto AMF, Coutinho IC, Correia
JB, Amorim MMR. Effectiveness of antenatal corticosteroids in reducing
respiratory disorders in late preterm infants: randomised clinical
trial. BMJ. 2011 2011/04/12;342(apr12 1):d1696-d.
67. Qublan HS, Malkawi HY, Hiasat MS,
Hindawi IM, Al-Taani MI, Abu-Khait SA, et al. The effect of antenatal
corticosteroid therapy on pregnancies complicated by premature rupture
of membranes. Clinical and experimental obstetrics & gynecology.
2001;28(3):183‐6.
68. Rotmensch S, Liberati M, Vishne
TH, Celentano C, Ben-Rafael Z, Bellati U. The effect of betamethasone
and dexamethasone on fetal heart rate patterns and biophysical
activities. A prospective randomized trial. Acta Obstet Gynecol Scand.
1999 Jul;78(6):493-500.
69. Schutte MF, Treffers PE, Koppe
JG, Breur W. The influence of betamethasone and orciprenaline on the
incidence of respiratory distress syndrome in the newborn after preterm
labour. British journal of obstetrics and gynaecology.
1980;87(2):127‐31.
70. Senat MV, Minoui S, Multon O,
Fernandez H, Frydman R, Ville Y. Effect of dexamethasone and
betamethasone on fetal heart rate variability in preterm labour: a
randomised study. Br J Obstet Gynaecol. 1998 Jul;105(7):749-55.
71. Shanks A, Gross G, Shim T,
Allsworth J, Sadovsky Y, Bildirici I. Administration of steroids after
34 weeks of gestation enhances fetal lung maturity profiles. American
Journal of Obstetrics and Gynecology. 2010 2010/07/01/;203(1):47.e1-.e5.
72. Silver RK, Vyskocil C, Solomon
SL, Ragin A, Neerhof MG, Farrell EE. Randomized trial of antenatal
dexamethasone in surfactant-treated infants delivered before 30 weeks’
gestation. Obstetrics and gynecology. 1996;87(5 Pt 1):683‐91.
73. Subtil D, Tiberghien P, Devos P,
Therby D, Leclerc G, Vaast P, et al. Immediate and delayed effects of
antenatal corticosteroids on fetal heart rate: a randomized trial that
compares betamethasone acetate and phosphate, betamethasone phosphate,
and dexamethasone. Am J Obstet Gynecol. 2003 Feb;188(2):524-31.
74. Taeusch HW, Frigoletto F,
Kitzmiller J, Avery ME, Hehre A, Fromm B, et al. Risk of respiratory
distress syndrome after prenatal dexamethasone treatment. Pediatrics.
1979;63(1):64‐72.
75. Teramo K, Hallman M, Raivio KO.
Maternal Glucocorticoid in Unplanned Premature Labor. Controlled Study
on the Effects of Betamethasone Phosphate on the Phospholipids of the
Gastric Aspirate and on the Adrenal Cortical Function of the Newborn
Infant. Pediatric Research. 1980 1980/04;14(4):326-9.
76. Urban R, Lemancewicz A, Przepiesc
J, Urban J, Kretowska M. Antenatal corticosteroid therapy: a comparative
study of dexamethasone and betamethasone effects on fetal Doppler flow
velocity waveforms. Eur J Obstet Gynecol Reprod Biol. 2005 Jun
1;120(2):170-4.
77. Hong S, Lee SM, Kwak DW, Lee J,
Kim SY, Oh JW, et al. Effects of antenatal corticosteroids in twin
neonates with late preterm birth (ACTWIN [Antenatal Corticosteroids in
TWIN late preterm neonates] trial): study protocol for a randomized
controlled trial. BMC Pregnancy Childbirth. 2019 Apr 3;19(1):114.
78. 03547791 N. Effects of ACS in
Twin With LPB: study Protocol for a RCT.Https://clinicaltrialsgov/show/nct03547791.
2018.
79. 03446937 N. Effect of Antenatal
Corticosteroids on Neonatal Morbidity.Https://clinicaltrialsgov/show/nct03446937.
2018.
80. Cartwright R, Crowther C,
Anderson P, Harding J, Doyle L, McKinlay C. Influence of fetal growth
restriction on neurocognitive function after repeat antenatal
betamethasone: secondary analysis of a randomised trial. Journal of
paediatrics and child health. 2019;55:12‐3.
81. Cartwright RD, Crowther CA,
Anderson PJ, Harding JE, Doyle LW, McKinlay CJD. Association of Fetal
Growth Restriction With Neurocognitive Function After Repeated Antenatal
Betamethasone Treatment vs Placebo: Secondary Analysis of the ACTORDS
Randomized Clinical Trial. JAMA network open. 2019;2(2):e187636.
82. group Bs, the G, Schmitz T,
Alberti C, Aupiais C, Ursino M, et al. Full versus half dose of
antenatal betamethasone to prevent severe neonatal respiratory distress
syndrome associated with preterm birth: study protocol for a randomised,
multicenter, double blind, placebo-controlled, non-inferiority trial
(BETADOSE). BMC Pregnancy & Childbirth. 2019;19(1):67-.
83. Vogel JP, Oladapo OT,
Pileggi-Castro C, Adejuyigbe EA, Althabe F, Ariff S, et al. Antenatal
corticosteroids for women at risk of imminent preterm birth in
low-resource countries: the case for equipoise and the need for efficacy
trials. BMJ Glob Health. 2017;2(3):e000398.
84. Althabe F, Belizan JM, McClure
EM, Hemingway-Foday J, Berrueta M, Mazzoni A, et al. A population-based,
multifaceted strategy to implement antenatal corticosteroid treatment
versus standard care for the reduction of neonatal mortality due to
preterm birth in low-income and middle-income countries: the ACT
cluster-randomised trial. Lancet. 2015 Feb 14;385(9968):629-39.
85. Lee VR, Kaimal AJ, Caughey AB.
Cost-effectiveness of antenatal late preterm steroids. American Journal
of Obstetrics and Gynecology. 2017;216(1):S233.
86. National Institute for Health and
Care Excellence. NICE guideline 25: preterm labour and birth. August,
2019. 2019 [cited December 6, 2019]; Available from:https://www.nice.org.uk/guidance/ng25
87. Committee on Obstetric P.
Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal
Maturation. Obstet Gynecol. 2017 Aug;130(2):e102-e9.
88. Mukerji A, Shah V, Shah PS.
Periventricular/Intraventricular Hemorrhage and Neurodevelopmental
Outcomes: A Meta-analysis. Pediatrics. 2015 Dec;136(6):1132-43.
89. Gotardo JW, Volkmer NFV, Stangler
GP, Dornelles AD, Bohrer BBA, Carvalho CG. Impact of
peri-intraventricular haemorrhage and periventricular leukomalacia in
the neurodevelopment of preterms: A systematic review and meta-analysis.
PLoS One. 2019;14(10):e0223427.
90. Saigal S, Doyle LW. An overview
of mortality and sequelae of preterm birth from infancy to adulthood.
Lancet. 2008 Jan 19;371(9608):261-9.
91. Zhang H, Liu J, Liu T, Wang Y,
Dai W. Antenatal maternal medication administration in preventing
respiratory distress syndrome of premature infants: A network
meta-analysis. Clinical Respiratory Journal. 2018;12(10):2480-90.
92. Gonzalez Garay AG, Reveiz L,
Velasco Hidalgo L, Solis Galicia C. Ambroxol for women at risk of
preterm birth for preventing neonatal respiratory distress syndrome.
Cochrane Database Syst Rev. 2014 Oct 31(10):CD009708.
93. Vogel JP, Souza JP, Gulmezoglu
AM, Mori R, Lumbiganon P, Qureshi Z, et al. Use of antenatal
corticosteroids and tocolytic drugs in preterm births in 29 countries:
an analysis of the WHO Multicountry Survey on Maternal and Newborn
Health. Lancet. 2014 Nov 22;384(9957):1869-77.
94. UN Commission, Born Too soon Care
Antenatal Corticosteroids Working Group. Dexamethasone versus
betamethasone as an antenatal corticosteroid (ACS). Aug 20, 2013. 2013
[cited Dec 6, 2019]; Available from:https://www.healthynewbornnetwork.org/hnn-content/uploads/ACS-Beta-vs-Dexa-130820.pdf
95. Gyamfi-Bannerman C, Zupancic JAF,
Sandoval G, Grobman WA, Blackwell SC, Tita ATN, et al.
Cost-effectiveness of Antenatal Corticosteroid Therapy vs No Therapy in
Women at Risk of Late Preterm Delivery: A Secondary Analysis of a
Randomized Clinical Trial. JAMA Pediatr. 2019 May 1;173(5):462-8.
96. Rosenbloom JI, Lewkowitz AK,
Sondgeroth KE, Hudson JL, Macones GA, Cahill AG, et al. Antenatal
corticosteroid administration in late-preterm gestations: a
cost-effectiveness analysis. Journal of Maternal-Fetal & Neonatal
Medicine. 2018;31(22):1-7.
97. Greensides D, Robb-McCord J,
Noriega A, Litch JA. Antenatal Corticosteroids for Women at Risk of
Imminent Preterm Birth in 7 sub-Saharan African Countries: A Policy and
Implementation Landscape Analysis. Global health, science and practice.
2018;6(4):644-56.